Tectonic Therapeutic has dosed the first subject with TX2100 in an open-label Phase 1 study for hereditary hemorrhagic telangiectasia, advancing the asset from preclinical research to human testing. The trial will evaluate safety and tolerability in a dose-escalation design, with subsequent expansion cohorts planned to gather preliminary efficacy signals and inform future development milestones.